|
Article Excerpt
Raises and Narrows 2009 EPS Guidance Guides to 2010 GAAP Diluted EPS Growth of 17 to 22 Percent
FRANKLIN LAKES, N.J., Nov. 3 /PRNewswire-FirstCall/ --
Third-Quarter 2009 Highlights: -- Record GAAP diluted EPS of $0.69, up 19.0 percent from $0.58 in third-quarter 2008 -- Record diluted EPS, excluding $0.06 in amortization of intangible assets from the 2003 spin-off, of $0.75, up 19.0 percent from $0.63 in third-quarter 2008 -- Total net revenues increased 17.8 percent to $14.8 billion -- Specialty pharmacy revenues increased 19.2 percent to a record of over $2.4 billion -- Generic dispensing rate increased 3.3 percentage points to a record 67.7 percent -- EBITDA per adjusted prescription increased to a record $3.27 from $3.19 in third-quarter 2008 -- Cash balance at quarter-end of $2.0 billion, after paying down $400 million of short-term debt September Year-to-Date 2009 Highlights: -- Record adjusted prescription volume of over 671 million, up 12.3 percent over 2008 -- Record EBITDA of $2.06 billion, a 12.2 percent increase over 2008 -- Cash flows from operations reached a record $2.5 billion, a three-fold increase over 2008 2009 Guidance Raised and Narrowed: -- Full-year 2009 GAAP diluted EPS guidance again raised and narrowed from previous guidance to a range of $2.58 to $2.60, now representing 21 to 22 percent growth over 2008. -- Full-year 2009 diluted EPS, excluding amortization of intangible assets, raised and narrowed to a range of $2.80 to $2.82, now representing 20 to 21 percent growth over 2008. 2010 Guidance: -- Full-year 2010 GAAP diluted EPS guidance of $3.05 to $3.15, representing growth of 17 to 22 percent over revised 2009 guidance. Full-year 2010 diluted EPS excluding amortization of intangible assets, of $3.28 to $3.38, representing growth of 16 to 21 percent over revised 2009 guidance.
Medco Health Solutions, Inc. today reported record third-quarter 2009 GAAP diluted earnings per share of $0.69, up 19.0 percent compared to $0.58 for the third quarter of 2008. Adjusting for the amortization of intangible assets that existed when Medco became a publicly traded company in 2003, third-quarter 2009 diluted earnings per share increased 19.0 percent to $0.75, from $0.63 in the third quarter of 2008. With continuing strong performance expected for the remainder of the year, GAAP diluted EPS for 2009 is now projected to grow 21 to 22 percent. On top of this increased 2009 growth expectation, 2010 GAAP diluted EPS is projected to grow an additional 17 to 22 percent.
Medco continues to demonstrate strong momentum in the marketplace. Annualized 2009 new-named and net-new sales stand at records of more than $10 billion and more than $8 billion, respectively. For 2010, annualized new-named sales climbed from the $2.8 billion reported last quarter to $4.1 billion, and net-new sales have also surpassed the $4 billion mark.
"Clients are drawn to the value driven by Medco's innovations, and they have expressed their strong interest and confidence in Medco by awarding us over $20 billion of new business since 2008. Of equal importance, we currently expect to retain 99 percent of our clients in 2010, a new company record," said David B. Snow Jr., Medco chairman and chief executive officer.
"We continue to leverage the power of our clinical innovations and highly efficient infrastructure to deliver improved care to patients, and reduced costs for the healthcare system - the essence of real healthcare reform. With a specialized patient-centric clinical model - a proven brandable difference - we expect our momentum to continue. This confidence is evident in our raised 2009 earnings guidance and strong 17 to 22 percent GAAP diluted EPS growth expected for 2010," said Snow.
Financial Results
Medco reported third-quarter total net revenues of $14.8 billion, an increase of 17.8 percent from third-quarter 2008 reflecting contributions from significant new client wins, as well as price inflation on brand-name drugs, partially offset by higher volumes of lower-priced generic drugs. Medco's generic dispensing rate increased 3.3 percentage points from third-quarter 2008 to a record 67.7 percent. The mail-order generic dispensing rate increased 2.3 percentage points to 58.1 percent and the retail generic dispensing rate increased 3.0 percentage points to 69.4 percent. Higher volumes of lower-priced generic drugs reduced net revenues for third-quarter 2009 by approximately $560 million, representing significant savings for Medco clients and members.
Total prescription volume, adjusting for the difference in days supply between mail-order and retail, of 220.2 million increased 14.1 percent from the third quarter of 2008. Mail-order prescription volume was 25.5 million, a 2.3 percent decrease from third-quarter 2008. Mail volume reflects a decline in brand-name drugs of 7.0 percent, partially offset by a 1.4 percent increase in generic drugs, where clients and members benefit from the highest savings. Significant new business wins drove strong growth in retail volumes, reaching 144.3 million, a 25.4 percent increase over third-quarter 2008. With the strong growth in retail volumes the adjusted mail-order penetration rate decreased 5.9 percentage points from third-quarter 2008 to 34.5 percent. (Please see Table 5 for the calculation of adjusted prescription volume.)
Gross margin for third-quarter 2009 increased 12.5 percent over third-quarter 2008, to a record $1.04 billion. As a result of the significant incremental retail volumes from new clients, the total gross margin percentage decreased 40 basis points to 7.0 percent from 7.4 percent in...
|
